The hypothesis of this study is that 2',3'-dideoxycytidine (ddC) will be safe and efficacious in the treatment of children with symptomatic HIV infection and who are intolerant of, or have disease progression on, zidovudine therapy.
Showing the most recent 10 out of 459 publications